Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.28 | 5.16605166052 | 5.42 | 5.75 | 4.6 | 30280 | 5.18743034 | CS |
4 | -0.07 | -1.21317157712 | 5.77 | 5.87 | 4.4006 | 20837 | 5.14705687 | CS |
12 | -1.205 | -17.4511223751 | 6.905 | 7.59 | 4.4006 | 19686 | 6.08874984 | CS |
26 | -6.0925 | -51.6641933432 | 11.7925 | 16.0675 | 4.4006 | 122318 | 12.17032522 | CS |
52 | -11.895 | -67.6044330776 | 17.595 | 23.5 | 4.4006 | 160720 | 15.27031574 | CS |
156 | -70.55 | -92.5245901639 | 76.25 | 92.5 | 4.4006 | 182084 | 26.99137842 | CS |
260 | -388.55 | -98.5542168675 | 394.25 | 449.75 | 4.4006 | 224950 | 75.457031 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관